MA-ROCKET-SOFTWARE
5.10.2021 15:02:11 CEST | Business Wire | Press release
Rocket Software , a global technology leader that develops enterprise software used by the world’s largest public and private sector companies, today named Milan Shetti the company’s next CEO, effective November 5. Milan will also retain his President title. Current CEO and co-founder Andy Youniss will become Executive Chairman, providing strategic insights and guidance to Rocket® in important areas where he has experience and expertise. Andy will also remain on Rocket’s Board of Directors.
“From Rocket’s creation almost 32 years ago, we set out to build a long-lasting software company that would make a difference in the world,” Youniss said. “I am incredibly proud of the company we have built, our 2,500 Rocketeers, the culture we embody, and the core values we live every day. This leadership transition is deeply important to me, and we have been intentional and thoughtful in every step of the process.”
Shetti joined Rocket in 2020 as Business Unit President and was named Rocket President earlier this year, overseeing all products in the company’s portfolio. Most recently, he held senior executive positions at Hewlett Packard Enterprise (HPE), including serving as Senior Vice President and General Manager of the multi-billion dollar storage business unit and previously as Chief Technology Officer of the Datacenter Infrastructure and Storage divisions.
“Milan is the right leader for this moment in Rocket’s history and for its future,” Youniss continued. “I have the utmost confidence that under his leadership, Rocket will continue to put our customers and partners first, deliver innovation and quality that matters, and enable even more legendary outcomes."
“I was captivated by how Rocket’s culture and technology strengthen each other,” said Shetti. “The connection Andy created between Rocket’s core values and the way we serve our customers and partners is what excites me most about leading Rocket in this next era, as we continue to accelerate the modernization of mission-critical systems and solve our customers’ and partners’ most pressing, highly technical challenges.”
“Andy has done a remarkable job building Rocket Software into a global technology leader, thoughtfully guiding the company’s growth and success. We are delighted to be able to continue working with him at the board level,” said David Humphrey, a Managing Director at Bain Capital Private Equity and a member of Rocket’s Board of Directors.
“Milan is an established technology leader with deep background in infrastructure management solutions. We are confident his skills and experience will enable Rocket to continue to advance its mission-critical portfolio of enterprise software solutions while furthering the commitment to its customers, employees and business partners,” added Max de Groen, a Managing Director at Bain Capital Private Equity and a member of Rocket’s Board of Directors.
Shetti began his career at Sun Microsystems as a software developer and advanced through a technical career path to technical director for the company’s data management group. After Sun Microsystems, Shetti led business development for IBRIX, Inc. before assuming the chief executive position. He holds a PhD in computer science from the University of Minnesota and a Master of Science in computer engineering from Syracuse University.
About Rocket Software
Rocket Software empowers organizations to create legendary impact in the world through innovation in legacy technologies. With deep expertise in IBM Z®, IBM Power®, and database and connectivity solutions, Rocket provides solutions that power tens of thousands of global businesses, solving real problems and making real-world impact. Rocket is a privately held U.S. corporation headquartered in the Boston area with centers of excellence strategically located throughout North America, Europe, Asia, and Australia. Rocket is a portfolio company of Bain Capital Private Equity.
Legacy Powers Legendary™
© 2021 Rocket Software, Inc. or its affiliates. All Rights Reserved.
Rocket® is a trademark of Rocket Software, Inc. and its subsidiaries, registered in the United States and other jurisdictions worldwide. All other trademarks cited herein are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211005005323/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
